Intralesional FLD-103
Phase 1
Intralesional FLD-103 is one of 18 therapeutic programs targeting Basal Cell Carcinoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
21 competitors in Basal Cell Carcinoma
#DrugCompanyPhaseTrials
1Erivedge
RocheApproved
Aldara
BBausch Health Americas, Inc.
Approved
Adriamycin
PfizerApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Adrucil
EElorac, Inc.
Approved
Visudyne
BBausch Health Americas, Inc.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Retin-a
VValeant Pharmaceuticals
Approved
Libtayo
RegeneronPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Intralesional FLD-103. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- FFeldan Therapeutics